These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 25271736)
1. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2. Kokontis JM; Lin HP; Jiang SS; Lin CY; Fukuchi J; Hiipakka RA; Chung CJ; Chan TM; Liao S; Chang CH; Chuu CP PLoS One; 2014; 9(10):e109170. PubMed ID: 25271736 [TBL] [Abstract][Full Text] [Related]
2. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc. Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227 [TBL] [Abstract][Full Text] [Related]
3. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262 [TBL] [Abstract][Full Text] [Related]
4. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Kokontis JM; Hay N; Liao S Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399 [TBL] [Abstract][Full Text] [Related]
5. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. Lu L; Schulz H; Wolf DA BMC Cell Biol; 2002 Aug; 3():22. PubMed ID: 12188931 [TBL] [Abstract][Full Text] [Related]
6. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells. Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321 [TBL] [Abstract][Full Text] [Related]
7. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. Yang ES; Burnstein KL J Biol Chem; 2003 Nov; 278(47):46862-8. PubMed ID: 12954644 [TBL] [Abstract][Full Text] [Related]
8. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling. Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729 [TBL] [Abstract][Full Text] [Related]
9. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC J Biomed Sci; 2011 Aug; 18(1):63. PubMed ID: 21859492 [TBL] [Abstract][Full Text] [Related]
10. Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase. Cifuentes E; Croxen R; Menon M; Barrack ER; Reddy GP J Cell Physiol; 2003 Jun; 195(3):337-45. PubMed ID: 12704643 [TBL] [Abstract][Full Text] [Related]
11. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519 [TBL] [Abstract][Full Text] [Related]
12. Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells. Jiang J; Pan Y; Regan KM; Wu C; Zhang X; Tindall DJ; Huang H Prostate; 2012 Feb; 72(2):225-32. PubMed ID: 21630295 [TBL] [Abstract][Full Text] [Related]
13. [Regulatory effect of Skp2 on the expression and transactivation of the androgen receptor in the progression of castration-resistant prostate cancer]. Song YT; Wu KJ; Wang XY; Na YG; Yin CM Zhonghua Nan Ke Xue; 2016 Feb; 22(2):122-7. PubMed ID: 26939395 [TBL] [Abstract][Full Text] [Related]
14. Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells. Cariaga-Martinez AE; López-Ruiz P; Nombela-Blanco MP; Motiño O; González-Corpas A; Rodriguez-Ubreva J; Lobo MV; Cortés MA; Colás B Cell Signal; 2013 Jul; 25(7):1586-97. PubMed ID: 23567263 [TBL] [Abstract][Full Text] [Related]
15. Castration-resistant prostate cancer cells are dependent on the high activity of CDK7. Pallasaho S; Gondane A; Kuivalainen A; Girmay S; Moestue S; Loda M; Itkonen HM J Cancer Res Clin Oncol; 2023 Jul; 149(8):5255-5263. PubMed ID: 36401094 [TBL] [Abstract][Full Text] [Related]
16. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis. Brown LK; Kanagasabai T; Li G; Celada SI; Rumph JT; Adunyah SE; Stewart LV; Chen Z Prostate; 2024 Jun; 84(9):877-887. PubMed ID: 38605532 [TBL] [Abstract][Full Text] [Related]
17. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer. Li B; Lu W; Yang Q; Yu X; Matusik RJ; Chen Z Prostate; 2014 Apr; 74(4):421-32. PubMed ID: 24347472 [TBL] [Abstract][Full Text] [Related]
18. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells. Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349 [TBL] [Abstract][Full Text] [Related]
19. Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression. Taneja SS; Ha S; Garabedian MJ J Cell Biochem; 2001; 84(1):188-99. PubMed ID: 11746527 [TBL] [Abstract][Full Text] [Related]
20. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer. Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]